Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an update.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its Indacaterol Acetate and Mometasone Furoate Powder for Inhalation. The product targets adults and adolescents with asthma who are inadequately controlled on existing inhaled corticosteroids and short-acting beta2-agonists.
The therapy combines a long-acting beta2-agonist with an inhaled corticosteroid and is described as the first once-daily ICS-LABA dual combination included in China’s 2022 National Reimbursement Drug List, offering a more convenient option for asthma management. Management said the approval marks a key milestone for its high-end inhalation technology platform and strengthens the foundation for future inhalation formulations in its development pipeline.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company focused on developing and manufacturing innovative and high-end medicines. The group operates across multiple therapeutic areas and is building a portfolio of advanced inhalation therapies for respiratory diseases in the Chinese market.
Average Trading Volume: 122,778,494
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$106.1B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.